Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Extremophiles : Life Under Extreme Conditions|August 1, 2019
Crystal structures of CDC21-1 inteins from hyperthermophilic archaea reveal the selection mechanism for the highly conserved homing endonuclease insertion siteHannes M Beyer, Kornelia M Mikula, Tatiana V Kudling, et al.Journal of Molecular Recognition : JMR|March 29, 2020
Epitope specificity of two anti-morphine monoclonal antibodies: In vitro and in silico studiesAlexander V Trofimov, Alexey V Sokolov, Alexandra Y Rak, et al.Frontiers in Immunology|June 4, 2021
Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor ControlDafne C A Quixabeira, Sadia Zafar, Joao M Santos, et al.Oncoimmunology|January 27, 2022
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1Dafne C A Quixabeira, Victor Cervera-Carrascon, Joao M Santos, et al.Frontiers in Immunology|July 21, 2023
An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippageSanteri Pakola, Dafne C A Quixabeira, Tatiana V Kudling, et al.Frontiers in Immunology|March 31, 2022
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck CancerJames H A Clubb, Tatiana V Kudling, Camilla Heiniö, et al.Molecular Therapy Oncolytics|January 26, 2023
Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumorsSaru Basnet, Joao M Santos, Dafne C A Quixabeira, et al.Molecular Therapy. Oncology|July 1, 2025
Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinomaVictor Arias, Tatiana V Kudling, James H A Clubb, et al.Journal for Immunotherapy of Cancer|January 27, 2025
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trialSanteri A Pakola, James H A Clubb, Tatiana V Kudling, et al.Cancer Gene Therapy|April 10, 2025
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomesTatiana V Kudling, Dmitrii Bychkov, James H A Clubb, et al.Pageof 2